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nce escaped from the quiescence niche, precursor
cells interact with stromal components that support
their survival, proliferation, and differentiation. We
examined interplays between human myogenic precursor
cells (mpc) and monocyte/macrophages (MP), the main
stromal cell type observed at site of muscle regeneration.
mpc selectively and speciﬁcally attracted monocytes in vitro
after their release from quiescence, chemotaxis declining
with differentiation. A DNA macroarray–based strategy
identiﬁed ﬁve chemotactic factors accounting for 77% of
chemotaxis: MP-derived chemokine, monocyte chemoat-
tractant protein-1, fractalkine, VEGF, and the urokinase
O
 
system. MP showed lower constitutive chemotactic activity
than mpc, but attracted monocytes much strongly than
mpc upon cross-stimulation, suggesting mpc-induced and
predominantly MP-supported ampliﬁcation of monocyte
recruitment. Determination of [
 
3
 
H]thymidine incorporation,
oligosomal DNA levels and annexin-V binding showed
that MP stimulate mpc proliferation by soluble factors, and
rescue mpc from apoptosis by direct contacts. We conclude
that once activated, mpc, which are located close by
capillaries, initiate monocyte recruitment and interplay with
MP to amplify chemotaxis and enhance muscle growth.
 
Introduction
 
Adult skeletal muscle regeneration results from activation,
proliferation, and fusion of myogenic precursor cells (mpc)
residing beneath muscle fiber basal lamina, the so-called
satellite cells (Hawke and Garry, 2001).
Tissue-specific microenvironmental cues delivered by stro-
mal components influence the fate of both adult stem cells
and their progeny (Spradling et al., 2001). The stem cell
niche represses differentiation of quiescent and self-renewing
cells, whereas the stromal support promotes cell survival and
proliferation and appears essential for differentiation of cells
escaped from the niche (Spradling et al., 2001). mpc likely
depend on such a stromal support to develop their myogenic
program (Seale et al., 2001).
Among stromal cells, macrophages (MP) play a major role
in maintenance of tissue homeostasis (Gordon, 1995). In
addition to phagocytosis and antigen presentation, these
cells may play a supportive role through a varied repertoire
of plasma membrane and secreted molecules (Gordon,
1995), as shown previously for erythroblasts, hepatocytes,
and neurons (Sadahira and Mori, 1999; Takeishi et al.,
1999; Polazzi et al., 2001).
Muscle damage induces massive MP infiltration of the
injury site (McLennan, 1996; Pimorady-Esfahani et al.,
1997). It was shown that irradiation-induced depletion of
monocyte/MP impairs muscle regeneration and that recon-
stitution of bone marrow restores regeneration; moreover,
boosted monocyte/MP influx enhances muscle regeneration
(Grounds, 1987; Lescaudron et al., 1999). The phagocytic
potential of resident MP is debated, but it is generally accepted
that newly recruited MP actively remove necrotic debris to
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facilitate subsequent muscle regeneration (McLennan, 1996;
Pimorady-Esfahani et al., 1997). In addition, MP likely fa-
vor muscle repair as suggested by in vitro studies reporting
on MP growth-enhancing effects on rodent and avian mus-
cle cells (Robertson et al., 1993; Cantini and Carraro, 1995;
Merly et al., 1999). If this view is increasingly acknowl-
edged, the mechanisms by which monocyte/MP are at-
tracted to injury sites and interplay with muscle cells are
largely unknown (Tidball et al., 1999). It has been shown
previously that peritoneal MP are chemoattracted by crushed
murine muscle homogenates but neither the cell source of
chemoattractants nor the chemokines involved in this effect
were identified (Robertson et al., 1993). Although myoblasts
have been occasionally shown to express some chemokine
transcripts (De Rossi et al., 2000; Reyes-Reyna and Krolick,
2000), the spectrum of mpc-released chemotactic factors
and their role in the recruitment of blood-borne cells have
not been delineated. Moreover, enhancement of mpc growth
by MP has not been documented in humans and its mecha-
nism remains unknown.
Understanding if and how blood-borne cells interplay
with mpc constitute a major goal for developing effective
cell therapies of muscle diseases. Moreover, monocyte/MP
are already considered as promising therapeutic tools. The
fine targeting capacities of MP make possible the use of
monocytes as shuttles for gene delivery to hidden or wide-
spread sites of tissue damage, e.g., dystrophic muscle (Par-
rish et al., 1996). In addition, MP can improve natural tis-
sue repair (Rapalino et al., 1998) and, admittedly, recreating
an appropriate stromal support in the setting of myoblast
transfer therapy could well be most useful to avoid massive
mpc death, a major limitation of this therapeutic approach
(Skuk and Tremblay, 2000).
These future prospects prompted us to set up a multistep
procedure to determine whether human mpc released from
quiescence can initiate monocyte chemotaxis, and to deci-
pher reciprocal influences of mpc and MP that may enhance
muscle growth.
 
Results
 
Human mpc in culture were at the stage of proliferation
(day 7), early differentiation (day 14), and late differentia-
tion (day 21) when grown without serum withdrawal (Fig.
1). In these conditions, all mpc do not achieve full differen-
tiation. However, myogenesis was assessed by both myotube
formation, the fusion index reaching 30% at day 21, and in-
creasing myogenin expression (Fig. 1).
 
Constitutive monocyte chemotaxis by mpc
 
Human mpc attract monocytes. 
 
In conventional chemotaxis
assays, human mpc attracted peripheral blood mononuclear
cells (PBMC), 5% of PBMC being specifically attracted at day
7, 9% at day 14, and 6% at day 21 (day 7 vs. 14 increase, P 
 
 
 
0.003; day 14 vs. 21 decrease, P 
 
  
 
0.05). Chemotaxis selec-
tively involved monocytes as assessed by enrichment of the at-
tracted cells in CD14
 
 
 
 cells (28% vs. 10%, P 
 
  
 
0.0001; Fig.
2 A). Enrichment in CD14
 
 
 
 cells was similar at all stages of
mpc culture and was not due to modulation of CD14 expres-
sion by the mpc-conditioned medium (unpublished data).
Similarly to PBMC, isolated human monocytes were at-
tracted by mpc with a peak of chemotaxis at day 14 (day 7
vs. 14 increase, P 
 
  
 
0.0001; day 14 vs. 21 decrease, P 
 
 
 
0.005; Fig. 2 B). Because chemotactic activity of a differenti-
Figure 1.  In vitro human mpc myogenesis. (A) mpc growth is 
expressed in number of cells/cm
2 (closed circles) and mpc differenti-
ation is estimated by the fusion index (open circles). (B) Myogenin 
immunoblot at days 7, 14, and 21 of mpc culture. (C–E) May-Grün-
wald Giemsa stain of mpc at days 7 (C), 14 (D), and 21 (E) of culture. 
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ating cell population may reflect both the state of differenti-
ation and the number of cells at each time point, we calcu-
lated chemotaxis normalized for 10
 
5
 
 mpc at each time point.
Fig. 2 C shows that normalized mpc chemotactic activity
was high at day 3, dropped at day 7, and progressively de-
clined at subsequent stages of differentiation. Differentiated
myotubes exhibited a low normalized chemotactic activity
similar to that of other cell types, including Jurkat and
MCF-7 cells. In standard culture conditions, the volume of
medium remains constant at each time point. To avoid bias
in calculation of normalized mpc chemotactic activity due to
variations of medium volume/cell number ratio, we mea-
sured chemotaxis at a constant ratio. Days 3 and 7 time
points exhibited the highest difference of volume/cell num-
ber ratio in standard conditions. Chemotaxis measured at a
constant ratio showed a decrease by 42% of mpc chemotaxis
from days 3 to 7 (P 
 
  
 
0.005; unpublished data), confirming
that mpc exhibit maximal individual chemotactic activity
shortly after their release from quiescence. A similar experi-
ment conducted at days 7 and 14 revealed a decline of che-
motaxis by 18% (unpublished data), very close to that ob-
tained by calculation (19%).
Normalized chemotaxis of mpc grown in differentiating
conditions to stimulate myotube formation showed a
more abrupt decrease than that of mpc allowed to sponta-
neously differentiate (unpublished data), confirming that
mpc differentiation is associated with a decline of their
chemotactic activity.
We assessed that monocyte attraction was directional by
varying mpc-conditioned medium concentrations in the
chemotaxis chambers. Increasing gradients from the upper
to the lower chamber induced migration of monocytes, but
neither absent nor reverse gradients did; moreover, chemo-
taxis correlated positively with the gradient magnitude
(unpublished data).
We used microvessel-derived endothelial cells to control
that mpc chemotaxis remains operative across an endothe-
lial layer. Using various mpc supernatant concentrations,
we observed a dose-dependent transendothelial mono-
cyte migration (P 
 
  
 
0.05; Fig. 2 D). This assay approxi-
mated the
 
 
 
in vivo situation as demonstrated by microana-
tomic study of human adult muscle. Indeed, a majority of
CD56
 
 
 
 satellite cells were located close by capillaries
(87% being 5–20 
 
 
 
m from a capillary). The mean distance
from a satellite cell nucleus to the closest capillary lumen
center was 12.7 
 
 
 
 7.5 
 
 
 
m.
 
DNA array yields a set of candidate chemotactic factors
in mpc. 
 
Instead of studying a preselected set of molecules to
identify the mpc-produced effectors of monocyte chemo-
taxis, we used an mRNA profiling technique allowing analy-
sis of a huge number of genes at once. Among the 588 genes
represented on the DNA macroarray membrane we used, 20
had products known to attract monocytes, of which five
were constitutively expressed by human mpc at days 7 and
14 of culture (Table I): monocyte chemoattractant protein-1
(MCP-1, CCL2; Zachariae et al., 1998), MP-derived che-
mokine (MDC, CCL22; Mantovani et al., 2000), fractal-
kine (FKN, CX
 
3
 
CL1; Bazan et al., 1997), VEGF (Sawano et
al., 2001), and urokinase type plasminogen-activator recep-
tor (uPAR; Resnati et al., 1996).
Confirmatory RT-PCR showed amplification products of
MCP-1, MDC, FKN, and VEGF transcripts at the expected
molecular weight (Fig. 3 A) in mpc culture. Both expression
and up-regulation of a functional uPAR/urokinase (uPA) che-
mokine-like system during human mpc differentiation were
reported previously (Quax et al., 1992; Chazaud et al., 2000).
Constitutive mpc release of MCP-1, MDC, and VEGF was
assessed by ELISA. MDC level normalized for 1
 
   
 
10
 
5
 
 cells
was higher at day 3 than at day 7 (P 
 
  
 
0.001), and at day 7
Figure 2.  Monocyte chemotaxis by mpc is specific, is regulated 
during myogenesis and is enhanced by mpc/MP interplay. (A) Percent-
age of CD14  cells among PBMC before (upper chamber) and after 
(lower chamber) chemotaxis toward mpc-conditioned medium. Each 
circle represents one experiment and bars are the means. (B) Monocyte 
chemotaxis toward mpc-conditioned medium during myogenesis. 
(C) Monocyte chemotaxis normalized to 1   10
5 cells. (D) Monocyte 
chemotaxis toward mpc-conditioned medium (day 14) across HMVEC 
monolayer. All results in (A–D) are means   SEM of at least three 
experiments run in triplicate. (E and F) Monocyte chemotaxis by 
(E) mpc (day 14) and (F) MP stimulated or not by the other cell type. 
Each symbol represents one experiment run in triplicate and variations 
are SD. Thick bar represents the mean. 
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than at day 14 (P 
 
  
 
0.05; Fig. 3 B). MCP-1 was undetectable
at day 3, appeared at day 7, and abruptly increased from days
7 to 14 (P 
 
  
 
0.02; Fig. 3 B). Consistently, RT-PCR did not
detect MCP-1 transcripts at day 3 (not depicted), and DNA
macroarray showed a threefold increase of MCP-1 mRNA
level from days 7 to 14 (Table I). VEGF level variations ex-
hibited a strong increase at day 21 (P 
 
  
 
0.005; Fig. 3 C). Sol-
uble FKN levels did not reach the high detection threshold
(70 pg/ml) of the ELISA we used (Foussat et al., 2001). How-
ever, immunofluorescence confirmed cellular expression of
FKN and the three other chemokines (Fig. 3, D–G). Labeling
of multinucleated cells unequivocally assessed a myogenic cell
expression. Cytoplasmic immunopositivity was observed for
all molecules. In addition, marked cell membrane labeling
was observed for FKN (Fig. 3 D).
 
MCP-1, MDC, FKN, VEGF, and the uPAR/uPA system are
the main effectors of monocyte chemotaxis by mpc. 
 
Func-
tional involvement of the detected molecules was assessed
using specific blocking antibodies (Fig. 4). Inhibition tests
could not be carried out at day 3, the time point associated
with the highest individual mpc chemotactic activity, be-
cause of a too low cell number in the conditions we used and
impracticability of increasing cell density without influenc-
ing myogenic differentiation. Therefore, inhibition tests
were performed at day 14, a time point associated with the
highest global mpc chemotactic activity. Monocyte chemo-
taxis decreased by 45% after MCP-1 inhibition (P 
 
  
 
0.01),
50% after MDC inhibition (P 
 
  
 
0.005), 62% after FKN
inhibition (P 
 
  
 
0.003), 44% after VEGF inhibition (P 
 
 
 
0.02), and 26% after uPAR inhibition (P 
 
  
 
0.02). Whole
Igs induced no effect. The presence of soluble FKN was as-
sessed by blocking the cognate receptor CX
 
3
 
CR1 on mono-
cytes, which inhibited chemotaxis by 59% (P 
 
  
 
0.005). To
further inhibit the complicated mechanism underlying the
Figure 3.  mpc constitutively express 5 monocyte chemotactic 
factors. (A) RT-PCR analysis of mpc mRNA at day 14 of FKN, MDC, 
MCP-1, VEGF, and  2M ( 2microglobulin). (B and C) ELISA for (B) 
MDC, MCP-1, and (C) VEGF of mpc supernatants. Each symbol 
represents one culture estimated in triplicate. (D–G) Immunolabeling 
of (D) FKN, (E) MDC, (F) MCP-1, (G) VEGF using FITC-conjugated 
secondary antibody. Blue, DAPI stain.
 
Table I. 
 
Gene expression by mpc at days 7 and 14 of culture
Intensity
 
a
 
Gene name GenBank accession no. Day 7  Day 14
 
Eotaxin (CCL11) D49372; Z75669; Z75668
 
  
 
Fractalkine (CX
 
3
 
CL1) U91835 35 35
GCSF (granulocyte colony–stimulating factor) X03438
 
  
 
I309 (CCl1) M57502
 
  
 
IL8 (interleukin-8) (CXCL8) Y00787
 
  
 
IP10 (interferon 
 
 
 
–induced protein) (CXCL10) X02530
 
  
 
LT-
 
 
 
 (lymphotoxin-
 
 
 
) D12614
 
  
 
MCP-1 (monocyte chemotactic protein 1) (CCL2) M24545 51 166
MCP-2 (CCL8) Y10802
 
  
 
MCP-3 (CCL7) X72308
 
  
 
MDC (CCL22) U83171 30 29
MIP1-
 
 
 
 (macrophage inflammatory protein 1 
 
 
 
) (CCL3) M23452
 
  
 
MIP1-
 
 
 
 (CCL4) J04130
 
  
 
MIP3-
 
 
 
 (CCL19) U77180
 
  
 
PDGFBB (B) X02811; M12783; M16288
 
  
 
RANTES (CCL5) M21121
 
  
 
TNF-
 
 
 
X01394
 
  
 
uPAR (CD87) U08839; M83246; X51675 7 7
VEGF C U43142 73 74
 
a
 
Measured in arbitrary units. 
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uPAR/uPA chemokine-like effect we targeted uPA, a strat-
egy previously proved efficient (Resnati et al., 1996). uPA
inhibition induced a 58% decrease of chemotaxis (P 
 
 
 
0.003). Because leukocytes integrate the various chemoat-
tractant signals they receive through multiple and promiscu-
ous receptors in a complex and still poorly understood fash-
ion (Foxman et al., 1997), we analyzed the effect of global
effector inhibition. Pooling blocking antibodies against MCP-1,
MDC, FKN, VEGF, uPAR, and uPA induced a 77% inhi-
bition of monocyte chemotaxis (P 
 
  
 
0.03; Fig. 4).
 
Monocyte chemoattractants are expressed by activated
satellite cells in vivo. 
 
In vivo relevance of our findings was
assessed by double immunostaining for CD56 and each ef-
fector on cryosections of a muscle biopsy showing pure ne-
crotizing myopathy, i.e., patchy degeneration/regeneration
without lymphocytic infiltrates. Coexpression of CD56 and
either MCP-1, MDC, or FKN was restricted to mononucle-
ated cells located in foci of postnecrotic regeneration (Fig.
5). Because expression of chemoattractants was not observed
in normal looking muscle areas, we assume that these
CD56-positive cells corresponded to either activated satellite
cells or myoblasts. In addition, immunopositivities were ob-
served in nonmyogenic mononuclear cells, presumably MP,
within or close to diseased areas (Fig. 5).
 
mpc/MP interplays
 
mpc and MP interact to amplify monocyte chemotaxis. 
 
As
compared to classically cultured mpc, mpc incubated 30 h
with MP-conditioned medium increased by 31% of their
chemotactic effect on monocytes (P 
 
  
 
0.02; Fig. 2 E). The
factors involved in constitutive mpc chemotaxis were also im-
plicated here because global inhibition decreased monocyte
chemotaxis by 67% (P 
 
  
 
0.006; unpublished data). MP
stimulation of mpc chemotaxis was specific because it was
not reproduced by mpc-conditioned medium (P 
 
  
 
0.62; un-
published data). Conversely, MP incubated with mpc-condi-
tioned medium increased their chemotaxis by 94% (P 
 
 
 
0.02; Fig. 2 F). This stimulation was not reproduced by MP-
conditioned medium (P 
 
  
 
0.80; unpublished data).
 
MP stimulate mpc growth. 
 
Cocultures at various mpc/
MP ratios were performed to further evaluate cell interplays.
First, we examined if MP operate phagocytosis of PKH26-
labeled mpc. No intracytoplasmic fluorescent signal was ob-
served in MP after 1–4 d of coculture, whatever the cell ratio
(ranging from 1:0.5 to 1:2), ruling out significant phagocy-
tosis of living mpc by MP (Fig. 6, A and B).
Next, mpc growth curves were established under culture
conditions allowing, or not, direct mpc/MP contacts. MP
Figure 4.  Five chemotactic systems ensure monocyte chemotaxis 
by mpc. Monocyte chemotaxis toward mpc-conditioned medium 
(day 14) was performed in the absence or presence of whole mice 
and rabbit IgGs or antibodies directed against MCP-1, MDC, VEGF, 
FKN, CX3CR1, uPAR, and uPA. Results are the means   SEM of 
three experiments run in triplicate.
Figure 5.  Activated satellite cells 
express the monocyte chemoattractants 
in vivo. Muscle biopsy from a patient 
with pure necrotizing myopathy was 
labeled for both chemoattractants (red) 
and CD56, a marker of myogenic cells, 
including satellite cells, myoblasts and 
regenerating muscle fibers (green). Colo-
calization (yellow in merging pictures) 
was observed in mononucleated cells 
within diseased areas (star in differential 
interference contrast (DIC) pictures) 
including shrunk muscle fibers undergoing 
postnecrotic regeneration. As usual in 
pathological muscle, the degenerative 
process and regeneration take place 
almost simultaneously within the same 
fiber. (A–D) Several mononucleated 
myogenic cells and two neighboring 
nonmyogenic cells express MCP-1. (E–H) 
Three myogenic cells and one neighboring 
nonmyogenic cell express MDC, whereas 
one regenerating fiber does not (top right). 
(I–L) One myogenic cell and one neigh-
boring nonmyogenic cell (CD56-) express 
FKN, whereas another regenerating fiber 
does not (bottom left). Blue, DAPI stain. 
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induced a dose-dependent increase of mpc density in both
conditions, but enhancement was stronger in conditions al-
lowing mpc/MP contacts (Fig. 6 C) than in cultures sepa-
rated by a porous filter (Fig. 6 D; 5.3-fold vs.
 
 
 
2.4-fold in-
crease of mpc density at day 7 of culture at the 1:10 [mpc/
MP] ratio, P 
 
  
 
0.02).
 
MP promote mpc proliferation by soluble factors and
mpc survival by direct contacts. 
 
mpc proliferation, quanti-
fied by [
 
3
 
H]thymidine incorporation, was strongly pro-
moted by MP-conditioned medium in a dose-dependent
way, an increase of 126% being observed at the 1:2 (mpc/
MP) ratio (P 
 
  
 
0.004; Fig. 7 A). mpc proliferation could be
specifically evaluated in cocultures because human MP are
postmitotic cells (van der Meer et al., 1982) that do not in-
corporate [
 
3
 
H]thymidine (Fig. 7 B). mpc proliferation was
moderately decreased by direct contact with MP, a decrease
of 27% being observed at the 1:2 (mpc/MP) ratio (P 
 
 
 
0.004; Fig. 7 B). Therefore, the net cell growth increase ob-
served in cocultures allowing cell–cell contacts could not be
attributed to a mitogenic effect. Rescuing of mpc from
apoptosis being linked to cell cycle exit (Dee et al., 2002), an
antiapoptotic effect mediated by MP contacts was likely.
This was confirmed by determination of oligosomal DNA
levels showing much lower apoptosis in cocultures (1:1 ra-
tio) than expected from addition of the levels determined in
separated mpc and MP cultures (Fig. 8 A). To discriminate
between variations of apoptosis affecting mpc and MP, we
performed double labeling with anti-CD56 antibody, a mpc
marker, and annexin-V, an early marker of apoptosis. As
compared with separate cultures, cocultures at 1:1 ratio
showed a decreased number of both apoptotic mpc (an-
nexin-V
 
 
 
, CD56
 
 
 
 
 
cells; 48.1 vs. 17.3%, P 
 
  
 
0.02) and ap-
optotic MP (annexin-V
 
 
 
, CD56
 
 
 
 cells; 63.1 vs. 39.9%, P 
 
 
 
0.01; Fig. 8, B–D). Rescuing of mpc from death could not
be attributed to soluble factors because mpc apoptosis re-
mained unchanged upon administration of MP-conditioned
medium (Fig. 8 A).
 
Discussion
 
We showed herein that human mpc could selectively and
specifically attract monocytes through an endothelial layer
in a dose-dependent fashion. This previously unreported
property of mpc varied according to the differentiation
stage, individual chemotactic activity of satellite cells being
high shortly after their release from quiescence and then de-
clining progressively to reach levels similar to that of other
cell types at time of late differentiation into multinucleated
myotubes. mpc were shown to produce five monocyte
chemoattractants accounting for 77% of whole mpc chemo-
taxis at day 14 of culture. They included three chemokines,
MDC, MCP-1, and FKN, one growth factor, VEGF, and
one proteolytic system with chemotactic activity, uPA/
uPAR. Effectors exhibited clearly different secretion profiles.
MDC, a recently identified CC-chemokine, was the earliest
detected signal for monocyte recruitment. MCP-1, a more
extensively studied CC-chemokine, took over from MDC at
time of later stages of myogenic differentiation.
MDC is not detected in normal human adult skeletal
muscle (Mantovani et al., 2000). It functions through the
CCR4 receptor, which is expressed by 6% of human mono-
cytes (Katschke et al., 2001), and at least another important,
as yet unknown, receptor (Mantovani et al., 2000). In addi-
tion to its chemotactic effect on monocytes, MDC activates
MP and enhances their phagocytic activity more rapidly
than does MCP-1,
 
 
 
in vivo (Matsukawa et al., 2000).
MCP-1 is produced, mainly under proinflammatory
conditions, by a large variety of cells (Zachariae et al.,
1998). CCR2 receptor, that is expressed by 71% of human
monocytes (Fantuzzi et al., 1999), mediates MCP-1 effects
on monocyte chemotaxis and activation (Zachariae et al.,
1998). Constitutive myogenic cell expression of MCP-1 was
reported previously in rat (Reyes-Reyna and Krolick, 2000)
Figure 6.  mpc/MP cocultures stimulate mpc growth. (A and B) 
coculture of PKH26-labeled mpc with MP (1:1 ratio) for 2 d shows 
absence of fluorescence in MP cytoplasms (circles). (C and D) Density 
of mpc in (C) direct or (D) indirect cocultures with MP at various 
seeding ratio. Results are the means   SEM of three experiments run 
in duplicate. 
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and human rhabdomyosarcoma (Astolfi et al., 2001) cell
lines, but not in primary human mpc cultures (De Rossi et
al., 2000). Interestingly, we did not detect MCP-1 at day 3,
a very early stage of culture, although a unique up-regulation
of MCP-1 mRNA expression was documented at subse-
quent stages. Such a differentiation-associated up-regulation
of MCP-1 expression was reported previously in both a
rhabdomyosarcoma cell line (Astolfi et al., 2001) and mono-
cytes/MP (Fantuzzi et al., 1999). Up-regulation of MCP-1
production is pivotal for amplification of chemotaxis (And-
jelkovic et al., 2000). Thus, MCP-1 appears as a secondary
signal for monocyte recruitment and MP activation, deliv-
Figure 7.  MP-secreted factors enhance mpc proliferation. 
[
3H]thymidine incorporation of mpc treated with (A) MP-
conditioned medium or (B) cocultured with MP. Each 
open symbol represents one separate experiment run in 
triplicate and closed circles represent the means   SEM.
Figure 8.  MP rescue mpc from apoptosis. (A) Oli-
gosomal DNA measurement in mpc cultures, mpc 
treated with MP-conditioned medium, MP, and 
mpc/MP cocultures. Results are the means   SD 
of three experiments run in duplicate. (B–D) mpc 
were (B) cultured alone or with (C) MP and labeled 
with annexin-V (green) and anti-CD56 antibodies 
(red). (B and C) Blue, DAPI stain. (D) Quantification 
of apoptotic cells among MP (black symbols) and 
mpc (white symbols) populations. Each symbol 
represents one separate culture.1140 The Journal of Cell Biology | Volume 163, Number 5, 2003
ered by mpc at time of MDC down-regulation in the setting
of chemotaxis amplification.
VEGF induces vascular cell chemotaxis, survival, and pro-
liferation, mainly through VEGF-R2 (Rissanen et al., 2002).
Among its nonvascular roles, VEGF is chemotactic for
monocytes through VEGF-R1, a receptor expressed by 83%
of human monocytes (Sawano et al., 2001). Muscle fiber ex-
pression of VEGF and VEGF-R2 is induced by ischemia
(Rissanen et al., 2002). It is associated with focal MP infil-
tration and vessel hyperplasia and might prevent muscle cell
death and support regeneration (Rissanen et al., 2002). Sim-
ilar VEGF effects may be at play after other types of muscle
injury as well.
The CX3C chemokine FKN contains a chemokine domain
fused to a mucin-stalk tethered to a transmembrane domain
with an intracytoplasmic tail (Bazan et al., 1997). FKN tran-
scripts have been detected previously in normal human mus-
cle homogenates (Bazan et al., 1997). In FKN-producing
cells, such as endothelial cells, 90% of FKN is membrane
bound at steady state and 10% is cleaved in a soluble form
(Imaizumi et al., 2000). Soluble FKN is angiogenic (Volin et
al., 2001) and chemotactic for monocytes (Bazan et al.,
1997; Chapman et al., 2000) through the cognate receptor
CX3CR1, that is expressed by 56% of human monocytes
(Ruth et al., 2001). In our work, both anti-FKN and anti-
CX3CR1 antibodies inhibited mpc chemotactic activity but
FKN could not be detected in supernatants by ELISA. This
was in keeping with previous evidence that attraction of hu-
man monocytes by FKN may occur at concentrations far be-
low the ELISA detection threshold (Chapman et al., 2000).
The uPA system mainly includes the receptor uPAR, its
ligand uPA and the matrix-bound inhibitor PAI-1 (Preissner
et al., 2000). The three components are markedly up-regu-
lated during muscle regeneration (Festoff et al., 1994; Lluis et
al., 2001) and at time of fusion in human mpc cultures
(Quax et al., 1992; Chazaud et al., 2000). uPA activates
hepatocyte growth factor (HGF) through cleavage of its ma-
trix-associated inactive precursor, which might trigger activa-
tion of quiescent satellite cells through c-met, the HGF re-
ceptor (Allen et al., 1995). In addition, the uPA system exerts
proteolytic and nonproteolytic roles operative in cell migra-
tion (Chazaud et al., 2000; Preissner et al., 2000). A soluble
form of truncated uPAR, present in body fluids (Sidenius et
al., 2000), mediates chemotaxis of myelomonocytic cells by
inducing signal transduction through an unknown trans-
membrane adaptor (Resnati et al., 1996). uPA exerts similar
chemotactic effects through uPAR and the same unknown
adaptor (Resnati et al., 1996). In our system, uPAR blockade
could not assess the proper role of soluble uPAR because it
interfered with uPA–uPAR binding at the membrane of
monocytes. Consistently, anti-uPA antibodies induced inhi-
bition of chemotaxis. A crucial role of uPA in muscle regen-
eration was demonstrated in uPA deficient mice (Lluis et al.,
2001), and reflects the multifunctional status of the uPA sys-
tem that could control satellite cell activation, monocyte che-
motaxis and mpc migration (Chazaud et al., 2000).
Finally, attempts to delineate the respective contribution
of each chemoattractant to chemotaxis exerted by a condi-
tioned medium containing multiple effectors constitute a
somewhat vain objective as: (a) chemotaxis results from the
integration of stimulating, inhibiting, and nullification sig-
nals converging on a common chemotaxis-initiating path-
way (Foxman et al., 1999); (b) as a result of receptor satura-
tion, homologous desensitization, or receptor sequestration,
chemoattractant concentration is not linearly correlated to
the observed chemotaxis (Foxman et al., 1997); and (c) che-
mokines may be inactivated upon cleavage by MMPs at the
NH2 terminus (McQuibban et al., 2002). For example,
truncated forms of MCP-1, that only lack two or three
amino acids and are likely detected by ELISA, were likely
present in our model that is associated with MMP up-regu-
lation (Guerin and Holland, 1995).
We showed that mpc and MP cross-stimulate their che-
motactic activity through soluble factors. Other cell types
were shown previously to interplay with monocyte/MP to
enhance MCP-1 production (Andjelkovic et al., 2000). The
activating factors remain undetermined, but activated mus-
cle cells are known to produce cytokines, including interleu-
kin-1 (Authier et al., 1999), interleukin-6 (Cantini et al.,
1995), TNF  (Saghizadeh et al., 1996), and MCP-1 (De
Rossi et al., 2000), that strongly up-regulate MCP-1 expres-
sion by monocyte/MP (Zachariae et al., 1998). Constitu-
tively, MP exerted a lower chemotactic activity than mpc,
but they amplified this activity more strongly than mpc did
upon reciprocal stimulation. This suggests that, once
recruited to the injured area, mpc-conditioned MP may
progressively substitute for mpc to recruit additional mono-
cytes. In addition, MP also attract myogenic cells (Rob-
ertson et al., 1993), which may favor their migration along
muscle fibers or even across the basal lamina toward the site
of postinjury regeneration (Carpenter and Karpati, 2001).
Immunohistochemical study of a human necrotizing myop-
athy confirmed in vivo expression of chemoattractants by ac-
tivated satellite cells and some regenerating muscle fibers. In
contrast, muscle fibers either intact or at an early necrotic
stage showed no expression of chemoattractants. In addition
to satellite cells, there were nonmyogenic mononuclear cells
expressing chemoattractants in areas of muscle regeneration,
presumably including MP, as reported previously in the set-
ting of inflammatory myopathies (Liprandi et al., 1999;
Confalonieri et al., 2000).
MP were also shown to stimulate human mpc growth.
MP-produced soluble factors promoted mpc proliferation. A
number of such factors have been identified, including IGF
I and II, HGF, FGFs, PDGF
BB, EGF, and interleukin-6
(Robertson et al., 1993; Hawke and Garry, 2001). In addi-
tion, MP contacts rescued a number of mpc from apoptosis.
Up to 35% of myoblasts die by apoptosis upon growth fac-
tor deprivation, whereas the others rapidly differentiate into
syncytial cells, a cell type more resistant to apoptosis (Dee et
al., 2002). Environmental factors that may rescue mpc from
apoptosis are unknown. Our results strongly suggest in-
volvement of adhesion molecules. Other cell types, includ-
ing erythroblasts, astrocytes, and neurons, may be rescued by
MP through VLA-4 ( 4 1 integrin)–VCAM-1 or FKN–
CX3CR1 interactions (Sadahira and Mori, 1999; Meucci et
al., 2000). These molecules are expressed by both mpc and
MP, as reported previously (Rosen et al., 1992; Sadahira and
Mori, 1999; Meucci et al., 2000), or assessed by DNA mac-
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spicuous labeling of membrane-bound FKN by mpc. As
other cell types, mpc might use FKN–CX3CR1 interactions
to bind MP (Fong et al., 1998) and deliver or receive antiap-
optotic signals (Meucci et al., 2000). In the same way, bind-
ing of recruited leukocytes by satellite cells and newly
formed myotubes involving VLA-4–VCAM-1 interactions
was documented previously in vitro and in vivo (Jesse et al.,
1998) and blockade of  1 integrin causes mpc apoptosis
(Vachon et al., 1997).
We propose a model in which, shortly after their release
from quiescence after muscle injury or the more limited ex-
ercise-induced myotrauma causing adaptive muscle hyper-
trophy (Hawke and Garry, 2001), satellite cells, either alone
or in combination with other resident cells types, initiate a
process aimed at providing an adequate stromal support to
their growth. The process first consists in mpc attraction of
circulating monocytes, which is facilitated by their remark-
able proximity to muscle capillaries (Schmalbruch and Hell-
hammer, 1977). Although differentiating into MP, the
blood-borne cells interplay with mpc to amplify the chemo-
tactic activity of the injured muscle area, and progressively
become the main local source of chemoattractants. At the
same time, MP phagocytose dead cells and/or act as potent
supportive cells for living mpc through delivery of both solu-
ble mitogenic factors and cell contact–mediated survival sig-
nals, ensuring good repair or maintenance of skeletal muscle.
This paper provides further support for therapeutic strate-
gies using monocytes as shuttles to treat muscular dystrophies
by the vascular route (Parrish et al., 1996). Moreover, it is
very unlikely that mpc transplanted into muscle for therapeu-
tic purposes would efficiently orchestrate the fine setting up
of the stromal support they need to grow and differentiate in
vivo, as many as 95% of transplanted mpc die shortly after
injection (Skuk and Tremblay, 2000) for nonmechanical
causes (Chazaud et al., 2003). Our results open the possibil-
ity of improving myoblast transfer therapy by providing
transplanted mpc with appropriate environmental cues.
Materials and methods
Cell cultures 
Unless indicated, culture media components were obtained from GIBCO
BRL and culture plastics were obtained from TPP AG.
Human mpc were cultured from muscle samples as described previously
(Chazaud et al., 2000). In standard conditions (spontaneous in vitro myogen-
esis), mpc were grown in Ham’s F12 medium containing 15% FCS (growing
medium) without serum withdrawal. In differentiating conditions, growing
medium was replaced by Ham’s F12 medium containing 5% FCS (differenti-
ating medium) at time of subconfluence. Only cultures presenting over 95%
CD56  (1:20 dilution, 123C3 clone; Sanbio/Monosan) cells were used.
PBMC were isolated from human blood using Ficoll Paque plus (Amer-
sham Biosciences) density gradient. Monocytes were isolated from PBMC
by an adhesion step (Fantuzzi et al., 1999). Purity, estimated by flow cy-
tometry after CD45-FITC (KC56 clone; Beckman Coulter) and CD14-PE
(RMO52 clone; Immunotech) labeling, ranged from 80 to 90%.
To obtain MP, monocytes were seeded at 0.5   10
6 cell/ml in Teflon
bags (AFC) in differentiating RPMI medium containing 15% human AB se-
rum for 8 d (van der Meer et al., 1982).
Jurkat cells were grown in RPMI containing 10% FCS. MCF-7 cells were
grown in DME containing 5% FCS and 1% nonessential amino acids.
mpc/MP coculture ratio ranged from 1:0.5 to 1:10. For growth and im-
munolabeling experiments, 1   2,000 cells/cm
2. In indirect cocultures,
MP were seeded in inserts (0.4- m diam pores; Falcon
TM, BD Biosciences)
placed over the mpc-containing well. In 96-well plates (proliferation and
apoptosis assays), 1   30,000 cells/well.
Conditioned media
Conditioned media were obtained by incubating cells in 24-well plates in
serum-free Ham’s F12 for 24 h in 0.5 ml (1 ). For chemotaxis assay at
constant cell/supernatant ratio, the volume of supernatant was adjusted ex-
actly to the mpc number (300  l for 10,000 mpc). Two and three times the
concentrations of mpc-conditioned media were obtained by proportional
reduction of medium in mpc culture. Cell stimulation by conditioned me-
dium was performed by incubating cells for 30 h with medium condi-
tioned the day before.
mpc growth and differentiation 
mpc density was determined by counting cells after trypsinization. Trypsin
treatment did not detach MP, as flow cytometry analysis of detached cells
after CD64-FITC (10.1; BD Biosciences) and CD14-PE labeling showed no
CD14  and  0.4% CD64  cells. Fusion index was calculated as de-
scribed previously (Authier et al., 1999). Myogenin immunoblotting was
carried out using 40  g mpc protein extract and M-225 antibody (1:200;
Santa-Cruz Biotechnology, Inc.).
Chemotaxis
Leukocytes (500,000 in serum-free Ham’s F12 medium) were deposited
into Falcon insert (3- m diam pores) put on top of a well containing con-
ditioned medium and plates were incubated at 37 C for 24 h. The num-
ber of cells present in the well was evaluated and expressed as percent-
age of number of deposited cells. Chemotaxis toward Ham’s F12
medium was considered as nonspecific chemotaxis, which value was
subtracted from observed values. No leukocyte was present at the insert
lower face. In some experiments, blocking antibodies were added in the
well at saturating concentrations (calculated from IC50 or from previous
studies): 3  g/ml anti–MCP-1 (Abcys), 3  g/ml anti-FKN (51637.11
clone; R&D Systems), 6  g/ml anti-MDC (R&D Systems), 6  g/ml anti-
VEGF (R&D Systems), 15  g/ml anti-CX3CR1 (Torrey Pines Biolaborato-
ries; Chapman et al., 2000), 4  g/ml anti-uPA (American Diagnostica,
Inc.), 5  g/ml anti-uPAR (American Diagnostica, Inc.; Chazaud et al.,
2002). Controls included addition of whole mice and rabbit IgGs (3  g/
ml each; Vector Laboratories).
Transendothelial chemotaxis was performed using human adult mi-
crovascular endothelial cells (HMVEC) cultured according to the manufac-
turer’s instructions (Biowhittaker). HMVEC were seeded at 10,000 cells/
cm
2 in Falcon inserts (3- m diam pores). 3 d after confluence, HMVEC
monolayer integrity was assessed in two wells by absence of Trypan blue
(0.2% in 0.1% BSA) translocation from upper to lower chamber after 3 h of
incubation. HMVEC were incubated overnight with conditioned medium
in the lower chamber before monocytes were added in the upper chamber
for 24 h. Monocytes present in the medium of the lower chamber were
counted. No monocyte was present at the insert lower face.
Phagocytosis 
PKH26 (Sigma-Aldrich)-labeled mpc were seeded with autologous or het-
erologous MP at different mpc/MP ratio and cultures were examined at
1–4 d using both fluorescence and phase-contrast microscopy.
ELISA 
MCP-1 (Beckman Coulter), MDC (R&D Systems), and VEGF (Cytimmune
Sciences Inc.) concentrations in mpc-conditioned medium were deter-
mined by ELISA. ELISA for FKN was conducted as described previously
(Foussat et al., 2001). Results were corrected according to the cell number
and are expressed in pg/ml for 1   10
5 cells.
mpc labelings 
mpc were labeled with primary antibodies for 2 h: 10  g/ml anti-MCP1,
50  g/ml anti-FKN,10  g/ml anti-MDC, 10  g/ml anti-VEGF, revealed us-
ing FITC-conjugated secondary antibody (1:100 dilution; Jackson Immu-
noResearch Laboratories) or biotin-conjugated secondary antibody (1:150
dilution; Jackson ImmunoResearch Laboratories) and FITC-streptavidin
(1:50 dilution; Vector Laboratories).
Cells were labeled with annexin-V–biotin (BD Biosciences) revealed by
streptavidin-FITC (Jackson ImmunoResearch Laboratories), and further la-
beled with anti-CD56 antibody revealed using a goat anti–mouse TRITC
antibody (1:100 dilution; Jackson ImmunoResearch Laboratories). At least
100 cells from randomly chosen fields (40  objective) were evaluated for
their labeling.
Coverslips were mounted in Vectashield containing DAPI (Vector Labo-
ratories). Controls included incubation with whole IgGs from species of
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Human muscle immunohistochemistry
Cross sections of frozen adult deltoid muscle biopsy samples were labeled
with mouse anti–human CD56 (1:20 dilution; NHK-1–RD1; Beckman
Coulter) revealed using peroxidase Vectastain ABC kit (Vector Laborato-
ries). The distance from the CD56  satellite cell nucleus to the lumen
center of the nearest capillary was determined on 50 satellite cells in
randomly chosen fields using the KS300 Imaging software (Carl Zeiss
MicroImaging, Inc.).
For double labeling, sections were labeled with mouse anti–human
CD56 revealed by goat anti–mouse-FITC (1:100 dilution; Jackson Immu-
noResearch Laboratories) and were further labeled for MCP1, FKN, MDC,
VEGF, and uPAR, revealed using TRITC-conjugated antibodies as de-
scribed in mpc labelings section.
Cell proliferation 
mpc were cultured with MP in Ham’s F12 medium, or with MP-condi-
tioned medium containing 1  Ci/ml [
3H]thymidine for 18 h. 50  l trypsin-
EDTA was added, radiolabeled DNA was recovered on MultiScreen
Harvest plates (Millipore) using a manual Harvester (PerkinElmer) and
quantified in a   counter.
Oligosomal DNA levels 
mpc were cultured with MP in Ham’s F12 medium, or with MP-conditioned
medium for 18 h, and treated using the Cell Death kit (Roche Diagnostic).
DNA array
Total RNA was prepared from mpc at days 7 and 14 of culture using the
RNeasy mini kit (QIAGEN). All further steps were performed according to
the manufacturer’s instructions in the Atlas Human Hematology/Immunol-
ogy array (BD Biosciences) kit. For days 7 and 14 samples, 9 and 7  g of
total RNA gave roughly similarly labeled cDNA: 989,000 and 963,000
cpm, respectively, that were deposited on membranes. Results were read
using a PhosphorImager (Amersham Biosciences) after a 4-d exposure
time. Analysis was performed using Image Quant software (Amersham Bio-
sciences), that allows background noise subtraction, correction for the
variation of density for housekeeping genes (all genes showed the same in-
tensity variation between the two membranes), and finally, comparison of
densitometric signals. Results were expressed in arbitrary units.
RT-PCR 
2   g of total mpc RNA was reverse transcribed and amplified using
OneStep RTPCR (QIAGEN) and specific primers. For FKN (primers in Lu-
cas et al., 2001) and MDC (primers in Katou et al., 2001), amplification
was performed at 94, 64, and 72 C for 30 s, 30 s, and 1 min, respectively,
for 38 cycles. For MCP-1 (GenBank/EMBL/DDBJ accession no. M24545),
the sense primer used was 5’-CCCAGTCACCTGCTGTTAT-3’ and the anti-
sense primer was 5’-AATTTCCCCAAGTCTCTGTATCTA-3’, amplification
was performed at 94, 55, and 72 C for 30 s for 38 cycles. For VEGF (prim-
ers in Bausero et al., 2000), amplification was performed at 94, 60, and
72 C for 30 s, 30 s, and 45 s, respectively, for 45 cycles. 10  l of amplifi-
cation products were subjected to electrophoresis on 2% agarose and
stained with ethidium bromide for visualization.
Statistical analysis
Excepted DNA array, all experiments were performed using at least three
different cultures. The t test was used for statistical analyses. P   0.05 was
considered significant.
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